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Conclusions: Replacing delineation based on guidelines by 
mathematical delineation corresponds more closely to 
microscopic spread probability, including a more systematic 
delineation of cranio-caudal tissue at risk. Deep and 
superficial clips and tissue distortion improve observer 
conformity, but do not systematically correspond to initial 
tumor location. Clips on the pectoral fascia tend to protract 
CTV unnecessarily towards the thoracic wall, thus increasing 
dose to organs at risk.  
Impact on inter-observer variation is ongoing. 
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Purpose/Objective: BRCA1 mutations contribute to about 5-
10% of breast cancer (BC) cases. The aim of the study was to 
analyze clinicopathological features, efficacy of oncological 
treatment, incidence of contralateral breast cancer (CBC) 
and other malignancies (OM) among BRCA1-positive BC 
patients (pts).  
Materials and Methods: Fifty one BRCA1-positive BC pts 
treated in Comprehensive Cancer Center in Bialystok, Poland 
between 1996 and 2010 were retrospectively analyzed. 61% 
of pts required multimodal treatment: surgery, 
chemotherapy and/or radiotherapy to breast tissue (BT), 
chest wall (CW) or regional lymph nodes (LNs) area while 
others (36.5%) were subjected only to surgical and/or 
chemotherapeutic treatment. Clinicopatological 
characteristic of pts were retrieved from clinical database. 
Results: The median age of the pts was 45.5 years (70% of pts 
were below 50). The majority of pts were at early clinical 
stage of the disease (I – 11.7%, II – 56.8%). The IIIrd stage was 
assessed in 21.6% of pts, IV – 3.9% of pts. The BRCA1 mutation 
types were 5283incC (59.5%), C61G (28.6%) and 4153 delA 
(11,9%). The negative estrogen, progesterone and HER2 
receptors status was reported in 70.3%, 74.5% and 66% of pts, 
respectively. The mastectomy was performed in 61% of pts, 
breast conserving therapy (BCT) in 35% of pts. The pts with 
metastatic disease at the time of diagnosis (3.9%) were 
treated with chemotherapy. Radiotherapy was performed on 
cobalt machine or linear accelerator with conventional 
fraction scheme. Patients were irradiated to CW – 43.7% 
(mean dose 49.8Gy) or BT – 56.3% (mean dose 49.4 Gy) 
plus/minus regional LNs – 50% (mean dose 50Gy). The mean 
treatment time accounted 35 days for pts after mastectomy 
and 45 days – after BCT. The boost was delivered by external 
beam radiotherapy in 93.8% of pts (mean dose 11.4 Gy) or by 
brachytherapy HDR – in 6,2% of pts (mean dose 10 Gy). In 
RTH-treated group regional recurrence occurred in 6.8% of 
pts who underwent mastectomy and in 5,3% of pts after BCT. 
No reoccurrence in LNs was observed in RTH group. However, 
in non-irradiated patients group, 3% developed recurrence in 
LNs and 10% of pts in CW area. With a median follow up of 
6.4 years, 13 pts (25.5%) developed distant metastases and 
11 pts (21.5%) suffered from another cancer. The most 
frequently reported malignancies were CBC (70%) and ovarian 
cancer (20%). Skin, coli uteri and parotid gland cancers were 
also observed. The LR recurrence or OM were not reported 
among pts with 4153 delA mutation. 
Conclusions: Breast cancer in BRCA1 carriers represents 
mostly negative status of steroid or HER2 receptors and is 
locally advanced at the time of diagnosis. Unfortunately, 
locoregional relapse or other malignancies are observed 
among this subset of pts. What is interesting, pts with 4153 
delA mutation did not demonstrate any adverse events. 
Identification of predictive factors is necessary to estimate 
the individual risk of developing LR recurrence or other 
cancers in BRCA1 carriers. Better understanding of 
correlations between type of BRCA1 mutations and treatment 
results is necessary for creating patients-directed approach. 
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Purpose/Objective: There are radiobilogical reasons 
justifying the use of hypofracctionation in breast cancer. 
Since the α/ß value of breast cancer has been estimated 
around 4 Gy, high fraction doses may be more efficient. 
However, this doses may also increase the frequency and 
severity of side effects in normal tissues. IMRT has the 
potential to improve target coverage and reduce 
inhomogeneities observed within the breast (and regional 
lymph nodes) and enables dose reduction to normal 
structures with the potential to reduce treatment toxicity 
improving cosmesis. According to the results published of 
phase III trials that compared standard treatment versus 
hypofractionated treatments, we started a hypofractionation 
protocol with Volumetric arc therapy (VMAT) with 
simultaneous boost to the tumor bed in those patients at high 
risk of local recurrence . The purpose of the study is to 
communicate the preliminary results in 40 patients treated in 
2013-2014. 
Materials and Methods: Inclusion criteria: left breast, 
irregular chest wall, prophylactic irradiation of 
supraclavicular area, voluminous breast and patient desire. 
 Treatment Protocol: 
· Targets: PTV1: mamary gland or anterior chest wall. PTV2: 
ipsilateral supraclavicular area. PTV3: tumor bed. 
· Dose and prescription: PTV1 and PTV2: 42,56 Gy (2,66 
Gy/fr). PTV3: 46,4 Gy (2,9 Gy/fr). 
· OAR constraints: contralateral breast: Dmax < 5 Gy; spinal 
cord: Dmax < 40 Gy; lung : V20 < 10 %, V10 < 20 %; coronary 
artery/ heart: V30 < 30 %; esophagus: Dmax < 40 Gy; thyroid: 
Dmax < 40 Gy. 
· Treatment planing system: Monaco 3.3 using Monte Carlo 
dose calculation algorithm. 
· Technique: tangencials arcs for breast and boost, and a 
semiarc for supraclavicular fold. 
